Avalyn समाचार और अपडेट

Avalyn Pharma Made Corporate and Clinical Presentations at ATS 2023 Including Results of Long-Term Treatment of Pulmonary Fibrosis with AP01

SEATTLE, May 23, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical com...

May 23, 2023 • Yahoo Finance

Avalyn to Participate in the Jefferies Global Healthcare Conference

BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biophar...

May 27, 2026 • Yahoo Finance

Avalyn Pharma outlines inhaled fibrosis push after IPO, with pivotal data ahead

Avalyn Pharma (NASDAQ:AVLN) executives outlined the company's inhaled pulmonary fibrosis strategy at...

Jun 05, 2026 • MSN

Avalyn Announces Pricing of Upsized Initial Public Offering

BOSTON, April 29, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN) (“Avalyn”), a clini...

Apr 29, 2026 • Nasdaq

Inhaled drug developer Avalyn files for U.S. IPO

Avalyn Pharma (AVLN), a biotech focused on developing inhaled therapeutics for the lung disorder pul...

Apr 10, 2026 • Seeking Alpha

Avalyn Completes Oversubscribed $100 Million Series D Financing to Further Advance Clinical Development of Novel Inhaled Therapies for Pulmonary Fibrosis

CAMBRIDGE, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmace...

Jul 22, 2025 • manilatimes

Avalyn’s New Twist on Older Lung Disease Drugs Attracts $175M for Clinical Trials

The lung disease idiopathic pulmonary fibrosis (IPF) has few available treatments, and that medical ...

Oct 01, 2023 • MedCity News

Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis

BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN) (Avalyn or the Company),...

Jun 17, 2026 • Business Insider

Avalyn Showcases Clinical Data Across Multiple Pulmonary Fibrosis Programs at ATS 2025

The MarketWatch News Department was not involved in the creation of this content. Topline results fo...

May 20, 2025 • MarketWatch

Lung disease drug developer Avalyn surges on public debut

Avalyn Pharma (AVLN), a biotech focused on developing inhaled therapeutics for the lung disorder pul...

Apr 30, 2026 • Seeking Alpha

Avalyn Pharma raises $300M in IPO, shares surge 64% on first day of trading

To continue reading this content, please enable JavaScript in your browser settings and refresh this...

Apr 30, 2026 • The Business Journals

Avalyn Pharma Rings the Opening Bell

Avalyn Pharma (Nasdaq: AVLN), visits the Nasdaq MarketSite in Times Square. The company is advancing...

Apr 30, 2026 • Nasdaq

Avalyn Pharma Begins IPO Process For Pulmonary Fibrosis Pipeline

Avalyn Pharma Inc. (AVLN) has filed to raise capital for its treatment pipeline development, accordi...

Apr 10, 2026 • Seeking Alpha

Avalyn raises $100M to advance inhaled versions of approved lung disease meds

Avalyn Pharma has added on $100 million to accelerate novel inhaled versions of approved drugs for l...

Jul 22, 2025 • FiercePharma

Avalyn Completes Successful Phase 1 Clinical Trials Of AP02, Its Novel Inhaled Formulation Of Nintedanib, Preparing For Phase 2 Development In Idiopathic Pulmonary Fibrosis

(MENAFN- GlobeNewsWire - Nasdaq) Topline data from the single- and multiple-ascending dose studies c...

Mar 31, 2025 • Mena FN

Avalyn Pharma Inc.

Avalyn Pharma Inc. company and executive profile by Barron's. View the latest AVLN company infomatio...

Jul 14, 2026 • Barron's

Avalyn CEO Lyn Baranowski Named a PharmaVoice 100 Honoree

CAMBRIDGE, Mass., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmace...

Oct 08, 2024 • Yahoo Finance

Avalyn Appoints Biopharmaceutical Industry Leader Kate Haviland to Board of Directors

BOSTON, March 05, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical co...

Mar 05, 2026 • Yahoo Finance

Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights

On track to complete enrollment of MIST Phase 2b trial of AP01 in progressive pulmonary fibrosis (PP...

Jun 03, 2026 • Business Insider

Avalyn, in pursuit of better lung drugs, banks $300M in an IPO

Avalyn Pharma on Wednesday raised $300 million in a large initial public offering that'll support de...

Apr 28, 2026 • Yahoo Finance

Avalyn Pharma Rings the Nasdaq Stock Market Opening Bell

Market open and close ceremonies take place daily at the Nasdaq MarketSite Studio in Times Square an...

Jul 10, 2026 • Nasdaq

Assessing Avalyn Pharma (AVLN) Valuation As Investors React To Recent Share Price Moves

Why Avalyn Pharma is on investors’ radar Avalyn Pharma (AVLN) has drawn attention after recent sha...

Jun 27, 2026 • Yahoo Finance UK

Avalyn Pharma Reports Data After One Year of Treatment in Ongoing AP01 Open-label Extension Trial in Adults with Pulmonary Fibrosis

Seattle, April 11, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical c...

Apr 11, 2023 • WAVY-TV

Avalyn Pharma Secures $35.5 Million Series B Financing, Broadens Development Portfolio

SEATTLE--(BUSINESS WIRE)--Avalyn Pharma Inc., a biopharmaceutical company focused on development of ...

Apr 27, 2020 • Business Wire

Avalyn Announces Additional Long-term Data on AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis to be Presented at the European Alliance of Associations for ...

BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biophar...

May 20, 2026 • Yahoo Finance

Avalyn Pharma Inc AVLN

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies...

Jun 10, 2026 • Morningstar

Avalyn Appoints Erin Lavelle, Seasoned Biopharma Finance Executive, to its Board of Directors

CAMBRIDGE, Mass., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmace...

Aug 04, 2024 • Yahoo Finance

Avalyn Pharma Sets IPO at 16.7 Million Shares Priced at $16-$18 Each

Avalyn Pharma on Wednesday plans to sell nearly 16.7 million shares at between $16 and $18 apiece in...

Apr 29, 2026 • MarketWatch

Avalyn to Present Patient-Centered Research on AP01 Delivery and Supportive Care Experiences at American Thoracic Society 2026 International Conference

Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled the...

May 05, 2026 • Markets Insider

Avalyn: Q1 Earnings Snapshot

Avalyn Pharma Inc. (AVLN) on Wednesday reported a loss of $26.9 million in its first quarter....

Jun 03, 2026 • The Advocate